Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DM005 |
Synonyms | |
Therapy Description |
DM005 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting EGFR and MET linked to monomethyl auristatin E (MMAE), which may have antitumor activity against EGFR and MET-expressing tumors (Journal for ImmunoTherapy of Cancer 2023;11). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DM005 | DM 005|DM-005 | EGFR Antibody 63 MET Antibody 36 | DM005 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting EGFR and MET linked to monomethyl auristatin E (MMAE), which may have antitumor activity against EGFR and MET-expressing tumors (Journal for ImmunoTherapy of Cancer 2023;11). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06515990 | Phase I | DM005 | A Study of DM005 in Patients With Advanced Solid Tumors | Recruiting | AUS | 0 |